Bimatoprost: A novel antiglaucoma agent

Cardiovascular Drug Reviews

Volumn 22, Issue 2, 2004, Pages 103-120

  Woodward, David F ^a   Phelps, R L ^a   Krauss, A H P ^a   Weber, A ^a   Short, B ^a   Chen, J ^a   Liang, Y ^a   Wheeler, L A ^a  

^a ALLERGAN INC   (United States)

Author keywords

2 Arachidonyl glycerol; Anandamide; Bimatoprost; Glaucoma; Prostaglandins

Indexed keywords

ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; CARBONATE DEHYDRATASE INHIBITOR; CYCLOOXYGENASE 2; DORZOLAMIDE; LATANOPROST; PRODRUG; PROSTAGLANDIN FP RECEPTOR AGONIST; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG;

BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; GLAUCOMA; HUMAN; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VISION;

EID: 3042837360     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2004.tb00134.x     Document Type: Review

References (55)

1. Abelson MB, Mroz M, Rosner SA, et al. Multicenter, open-label evaluation of hyperemia associated with use of bimatroprost in adults with open-angle glaucoma or ocular hypertension. Adv Ther 2003;20:1-13.
2. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-440.
3. Becker B. The decline in aqueous secretion and outflow facility with age. Am J Ophthalmol 1958;46: 731-736.
4. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, Vandenburg AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001;131:19-24,
5. Buhr MM, Gruber MY, Riley JC, Carlson JC. The effect of prolactin pretreatment on prostaglandin F2 alpha-associated structural changes in membranes from rat corpora lutea. Am J Obstet Gynecol 1983;145: 263-268.
6. Burnstein SH, Rossetti RG, Yagen B, Zurier RB. Oxidative metabolism of anandamides. PGs Other Lipid Mediat 2000;61:29-41.
7. Camras CB, Neely DG, Weiss EL. Latanoprost-induced iris color darkening: a case report with long-term follow-up. J Glaucoma 2000;9:95-98.
8. Chen J, Senior J, Woodward DF, et al. Studies of human isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Submitted.
9. Coleman AL, Lemer F, Bernstein P, Whitcup SM. A 3-month randomized controlled trial of bimatoprost (Lumigan®) versus timolol/dorzolamide (Cosopt®) in patients with glaucoma or ocular hypertension. Ophthalmology; In press.
10. Davies SS, Ju W-K, Neufeld AH, Abran D, Chemtob S, Roberts LJ. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocular Pharmacol Ther 2003;19:45-54.
11. Dubiner H, Cooke D, Dirks M, Stewart W, Vandenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30 day comparison with latanoprost. Surv Ophthalmol 2001; 45(Suppl 4):S353-S360.
12. Gabelt B, Gottanka J, Lutjen-Drecoll E, Kaufman PL. Aqueous humor dynamics and trabecular meshwork and anterior ciliary muscle morphologic changes with age in Rhesus monkeys. Invest Ophthalmol Vis Sci 2003;44:2118-2125
13. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-121.
14. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003;110:609-614.
15. Grossman CJ. Interactions between the gonadal steroids and the immume system. Science 1985;227: 257-261.
16. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120(10):1268-1279.
17. 2α by human and rabbit ocular tissue. J Ocular Pharmacol Ther 2003;19:97-103.
18. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286-1293.
19. Hutchinson SM, Hammond TG, Coleman R, Horton AA. Effects of eicosanoids on parameters in isolated rat hepatocytes and isolated rat hepatocyte couplets: Protective effects of eicosanoid receptor antagonist. J Lipid Mediators Cell Signaling 1997;15:249-254.
20. Indrei A, Nechifor M, Mihalache G, Grigore M, Cocu F, Indrei LL. The influence of some prostaglandin analogues on the female rat ovary and uterine tube epithelium. Rev Med Chir Soc Med Nat Iasi 1999;103: 172-176.
21. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-713.
22. 2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. J Pharmcol Exp Ther 2003;304:238-245.
23. Kozak KR, Crews BC, Morrow JD, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol ester and ethanolamides. J Biol Chem 2002;277:44877-44885.
24. Laibovitz RA, Vandenburgh AM, Felix C, et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol. Dosing, efficacy and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol 2001;119:994-1000.
25. 2 agonist) on Cyr 61 and Connective Tissue Growth Factor gene expression. J Biol Chem 2003;278: 27267-27277.
26. Maddox YT, Ramwell PW, Shiner CS, Carey EJ. Amide and 1-amino derivatives of prostaglandins as prostaglandin antagonists. Nature 1978;273:549-552.
27. Marnett LJ. Selective oxygenation of endocannabinoids by cyclooxygenase-2 and its biological consequences. FASEB J 2003;17:Aa1183.
28. Matias A, Chen J, DePetrocellis L, et al. Prostaglandin ethanolamides (prostamides): In vitro pharmacology and metabolism. J Pharmacol Exp Ther; In press.
29. Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 2002;47:34-40.
30. Nelson P, Aspinall P, Papasouliotis O, Papasouliotis O, Warton B, O'Brien C. Quality of life in glaucoma and its relationship with visual function. J Glaucoma 2003;12:139-150.
31. Netland PA, Landry T, Sullivan EK. et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-484.
32. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the intraocular pressure lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63.
33. Noecker RJ, Earl ML, Mundorf T, Peace J, Williams, RD. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 2003;20:121-128.
34. Parrish RK, Palmberg P, Sheu W-P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked evaluator multicenter study. Am J Ophthalmol 2003;135:688-703.
35. Richter M, Krauss AH-P, Woodward DF, Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 2003;44:4419-4426.
36. 2 alpha on plasma membrane changes during luteolysis in the rat. Endocrinology 1989;12:1564-1570.
37. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol 2001;432:211-213
38. 2+ mobilization studies. PGs LTs Ess Fatty Acids 2003;68:27-33.
39. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45(Suppl 4):S361-S368.
40. nd communication: Repeated topical administration on the eye. Arzneimittelforschung 1999;49:234-239.
41. rd communication: Tissue distribution after topical administration on the eye studied by whole body autoradiography. Arzneimittelforschung 1999;49:240-249.
42. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002;47:S6-S12.
43. Stewart WC, Kolker AE, Stewart JA, et al. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003;135:314-320.
44. 2α. An ultrastructural study in Rhesus and Cynomolgus monkeys. Mech Aging Dev 1990;51:101-120.
45. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-1304.
46. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128:8-14.
47. Weidenbach H, Scheibner J, Stange EF, Adler G, Bekh K. Reduction of bile secretion by prostaglandins in the rat in vivo. Life Sci 1996;58:1531-1538.
48. Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther 2002;19:275-281.
49. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41(Suppl 2):S129-S138.
50. 2α effects on intraocular pressure negatively correlate with FP-receptor stimulation. Invest Ophthalmol Vis Sci 1989;30:1838-1842.
51. 2α with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol 2000;136: 1933-1943.
52. Woodward, DF, Andrews SW. Burk RM, Gaust ME. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents. U.S. Pat. No. 5352708, 1994.
53. Woodward DF, Krauss A H-P, Chen J, et al. Pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2001;45(Suppl 4):S337-S345.
54. Woodward DF, Krauss A-HP, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J Pharmacol Exp Ther 2003;305:772-785.
55. 2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 1997;272:21181-21186.